The main highlights are in the field of the early stages, of course, and so trying to explore the role of chemo and the IO in the adjuvant and neoadjuvant treatment. So trying to understand the better sequencing also for patients with oncogenic positive disease, to understand if this combination may be available and active, even in this field. Or if in the early stages, we have to look at only early treatment by oncogenic inhibition...
The main highlights are in the field of the early stages, of course, and so trying to explore the role of chemo and the IO in the adjuvant and neoadjuvant treatment. So trying to understand the better sequencing also for patients with oncogenic positive disease, to understand if this combination may be available and active, even in this field. Or if in the early stages, we have to look at only early treatment by oncogenic inhibition. So these are the major field to look at in the next month.